West Paces Advisors
TCRT icon

West Paces Advisors’s Alaunos Therapeutics TCRT Stock Holding History

West Paces Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9 Hold
10
– – ﹤0.01% 691
2026
Q2 		$23 Buy
+10
New +$26 ﹤0.01% 763
2025
Q2 		– Sell
-10
Closed -$15 – 515
2025
Q1 		$15 Hold
10
– – ﹤0.01% 563
2024
Q4 		$19 Hold
10
– – ﹤0.01% 556
2024
Q3 		$32 Hold
10
– – ﹤0.01% 546
2024
Q2 		$70 Hold
10
– – ﹤0.01% 562
2024
Q1 		$181 Hold
10
– – ﹤0.01% 573
2023
Q4 		$106 Hold
10
– – ﹤0.01% 603
2023
Q3 		$198 Hold
10
– – ﹤0.01% 511
2023
Q2 		$765 Hold
10
– – ﹤0.01% 503
2023
Q1 		$945 Hold
10
– – ﹤0.01% 512
2022
Q4 		$974 Buy
+10
New +$1.45K ﹤0.01% 479

Other funds holding TCRT

BOK Financial
BOK Financial Tulsa, Oklahoma $6.69B AUM 26.84% 1-Year Est. Return
Key Financial Inc
Key Financial Inc West Chester, Pennsylvania $614M AUM 14.43% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
Newbridge Financial Services Group
Newbridge Financial Services Group Boca Raton, Florida $868M AUM 42.47% 1-Year Est. Return
NBC Securities
NBC Securities Birmingham, Alabama $1.47B AUM 20.38% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

West Paces Advisors's TCRT Position: Q3 2026 in Review

West Paces Advisors held its Alaunos Therapeutics (TCRT) position steady in Q3 2026 at 10 shares worth $9. The position accounts for ﹤0.01% of the portfolio, ranked #691.

West Paces Advisors first reported a position in TCRT in Q4 2022 and has held it in 12 quarters since. The position peaked at $974 in Q4 2022. 8 funds tracked by Wall St. Rank hold TCRT as of Q3 2026.

  • West Paces Advisors held 10 shares of Alaunos Therapeutics worth $9 as of Q3 2026.
  • West Paces Advisors left its Alaunos Therapeutics share count unchanged in Q3 2026.
  • Alaunos Therapeutics made up ﹤0.01% of West Paces Advisors's portfolio in Q3 2026, its #691 holding.
  • West Paces Advisors first reported a position in Alaunos Therapeutics in Q4 2022 and has held it in 12 quarters since.
  • West Paces Advisors's Alaunos Therapeutics position peaked at $974 in Q4 2022.
  • 8 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2026.

Based on West Paces Advisors's 13F filing for Q3 2026, filed 13 Oct 2026.